Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Next Previous
Trial Profile

Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Jun 2019 Results presented in an ALK-Abello media release.
  • 24 Jun 2019 According to an ALK-Abello media release, the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities. The data used in the filing include results from the Phase III clinical trial finalised in 2017.
  • 27 Sep 2017 According to ALK's media release, Japan's Ministry of Health, Labour and Welfare has approved the New Drug Application submitted by its partner Torii Pharmaceutical Co Ltd, for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, which will be branded CEDARCURE.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top